Versartis Publishes Preclinical Abstracts For Two Product Candidates At 2009 American Diabetes Association Scientific Sessions

Versartis Publishes Preclinical Abstracts For Two Product Candidates At 2009 American Diabetes Association Scientific Sessions
Versartis, Inc., a new company developing novel biologics with enhanced properties for patients with metabolic diseases, published abstracts for preclinical data on its two product candidates, VRS-859 (exenatide-rPEG) and VRS-808 (glucagon-rPEG), at the American Diabetes Association Scientific Sessions annual meeting beginning today in New Orleans. Versartis, through a unique licensing agreement with Amunix, Inc.

Erectile Dysfunction Might Be Associated With Chronic Periodontal Disease: Two Ends Of The Cardiovascular Spectrum

Erectile Dysfunction Might Be Associated With Chronic Periodontal Disease: Two Ends Of The Cardiovascular Spectrum
UroToday.com - Together with Drs. Heruti, Bechor, Justo and Galor, we studied 815 Israeli male adults of whom 305 had complete data and were included in the statistical analysis. In the analyzed population, 2.1% of people without erectile dysfunction (ED) had advanced periodontal disease (defined as recession of periodontal bone of 6 mm or more) in comparison to 9.8% of the mild ED and 15.8% of the moderate/severe ED populations, respectively.

New Study Uncovers Mode Of Action Of Enzyme Linked With Several Types Of Cancer

New Study Uncovers Mode Of Action Of Enzyme Linked With Several Types Of Cancer
Scientists at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal have discovered a key mechanism used by cells to efficiently distribute chromosomes to new cells during cell multiplication. Published in the journal Molecular Cell, the study is the first to demonstrate that this mechanism relies on the polo kinase, an enzyme implicated in several cancers. Inhibiting this mechanism could be key to developing effective therapies to treat cancer.